Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The fibromuscular dysplasia (FMD) market is influenced by its status as a rare disease. Limited awareness, research, and available treatments contribute to the unique dynamics of the FMD market, emphasizing the need for targeted interventions and specialized care.
Demographic trends are found to affect FMD prevalence, as the elderly and the ones teenagers have more opportunities to contract FMD. Although this might not look very important, gender also plays a significant role, as females are more likely to be affected by FMD. These demographic factors hold impact in regarding market dynamics definition of the patients and demand to eliminate any gender-specific treatments.
Genetics and family lineaments are not excluded from the list of free market forces of FMD. The data on gene involvement in FMD gets medical scientist to consider customized therapy and testing for risk factor; this has a subsequent role in changing the general market atmosphere.
Misdiagnosis and failure to diagnose also lead to market issues. The difficulty of correctly figuring out the FMD's nature requires the development of better diagnostic tools and spreading the news among healthcare professionals and plant owners in such as way that will increase the possibility of early detection.
The progression of imaging devices and diagnostics technologies in an vital point for marketplace fluctuations. Development of new imaging methods without invasiveness provide doctors with the opportunity to diagnose and monitor FMD more precisely, and also it usually affects the decisions of treating and ‘market situation’.
The market landscaping, in turn, is affected with the treatment options that are available for FMD. In terms of interventional procedures there is angioplasty and stenting which speak values when it comes to the management of FMD-related vascular complications and this outcome causes the demand for both interventional cardiology and radiology services to go high.
The process of research and development that is ongoing, but on-going, still play a very remarkable role through the FMD market dynamics. Investments in determinations of the pathophysiology of FMD and following up novel therapeutics approaches play the role of targeted treatments’ development which as result has an impact on the market expansion.
The accessibility of specialized care for FMD patients influences market factors. Disparities in healthcare resources and the availability of specialized centers impact patient access to FMD-specific treatments, creating variations in demand and overall market trends.
The state of healthcare infrastructure and the affordability of specialized healthcare services impact market dynamics. Economic considerations, including the cost of diagnostic tests and interventional procedures, play a role in patient access to FMD treatments and overall market trends.
Fibromuscular Dysplasia Market Highlights:
Fibromuscular Dysplasia Market Overview
Fibromuscular Dysplasia Market Size was valued at USD 0.44 Billion in 2023. The Global Fibromuscular Dysplasia industry is projected to grow from USD 0.45 Billion in 2024 to USD 3.63 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.21% during the forecast period (2024 - 2032). Fibromuscular dysplasia (FMD) is a disease that causes abnormal cell development in the artery wall, which results in narrowing, i.e., stenosis, and enlargement, i.e., aneurysm of the medium-sized arteries in the body.
According to a study published in the Insights into Imaging in 2015, it is found that the prevalence of fibromuscular dysplasia is estimated to be 4%-6% in the renal arteries and 0.3%-3 % in the cervico-encephalic arteries. Fibromuscular dysplasia is most frequently revealed in the kidneys of young patients associated with resistant hypertension secondary to fibrodysplastic renal artery stenosis. It is also reported that fibromuscular dysplasia is found in around 1% of the hypertensive patients, and is the second leading cause of renovascular hypertension after atherosclerotic disease.
Notably, rising prevalence of fibromuscular dysplasia and increasing R&D expenditure are the key factors driving the fibromuscular dysplasia market. In the year 2016, the R&D expenditure in the pharmaceutical Industry was USD 43,047.9 million, suggested by European Federation of Pharmaceutical Industries and Association.
Various other factors such as increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the fibromuscular dysplasia market. According to the Eurostat data, it is observed that among the European Union Member States, the highest value of healthcare expenditure was recorded in Germany, i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion, in 2014.
Despite these driving factors, there are some challenges with fibromuscular dysplasia market. Side-effects of treatment, expiration of patented drugs, the presence of misbranded drugs, and poor healthcare system in low and middle-income countries may hamper the growth of the market to a great extent over the review period 2024-2032.
Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Medical Device Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
Fibromuscular Dysplasia Market Segmentation
The fibromuscular dysplasia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of the type, the fibromuscular dysplasia market is classified as multifocal fibromuscular dysplasia, and focal fibromuscular dysplasia.
On the basis of the diagnosis, the fibromuscular dysplasia market is classified as physical examination, blood test, catheter-based angiography, doppler ultrasound, computerized tomography (CT) angiogram, magnetic resonance imaging (MRI), and others
On the basis of the treatment, the fibromuscular dysplasia market is classified as surgery, medication, and others. The surgery segment is further sub-segmented into percutaneous transluminal angioplasty (PTA), and surgical revascularization. The medication segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, diuretics, calcium channel blockers, and beta blockers.
On the basis of the end-user, the fibromuscular dysplasia market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.
Fibromuscular Dysplasia Market Regional Analysis
The Americas dominate the fibromuscular dysplasia market owing to the rising prevalence of fibromuscular dysplasia and high healthcare expenditure. In 2015, the total health expenditure in the U.S. was reported to be USD 3.2 trillion, and hospital care accounted for a share of 32.3%, suggested by Centers for Disease Control and Prevention.
Europe holds the second position in the fibromuscular dysplasia market. It is found that the rising research & development expenditure, and amendments in the reimbursement policies in the healthcare are likely to drive the European market.
The Asia Pacific region is the fastest growing fibromuscular dysplasia market owing to the developing healthcare technology, and huge patient pool. Healthcare expenditure of various Asia Pacific countries is also growing steadily. As per the Australian Institute of Health and Welfare in the years 2015-2016, the total healthcare expenditure in Australia was recorded to be USD 170.4 billion, which was around 3.6% higher than the expenditure of 2014-2015.
The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.
Fibromuscular Dysplasia Market Key Players
Some of the key players in the fibromuscular dysplasia market are:
- Alkermes Pharma Ireland Limited
- ALVOGEN
- Aspen Surgical Products, Inc.
- AstraZeneca
- B. Braun Melsungen AG
- Bayer Healthcare Pharmaceuticals Inc.
- Becton
- Dickinson and Company
- Bristol-Myers Squibb
- Dainippon Sumitomo Pharma Co., Ltd
- Ethicon, Inc.
- Merck
- Novartis
- Pfizer
- Sanofi-Aventis
- Smith & Nephew plc
- Medtronic
- Stryker Corporation
- Watson Pharma Private Limited
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
